College of Medical, Veterinary & Life Sciences

This support scheme is focused on the translation of research towards impact. Fundamental or discovery research is out with remit.

It is important that applicants can demonstrate how their project fits within the remit and provide a short background of their underpinning research, explaining how the funds requested can contribute towards the successful progression of their work with a focus on clear outcomes.

Collaborations with external partners is encouraged, but not necessary for your funding application. Examples of eligible partners include private sector, government bodies, public sector organisations including the NHS, charities, NGOs and other third sector organisations. If such a collaboration is proposed in your applications, you must ensure that formal collaboration agreements are in place with any external partners before the beginning of your project. This can be included as a letter of support. The TRI recommend that you discuss this with your external partners or collaborators at an early stage of the proposal development and before applying for funding.

Principal investigators of IAA awards must be a University of Glasgow employee and have a staff number, as well as being contracted for the duration of the project. Early Career Researchers can apply for standard IAA funding as the principal investigator of a project. Written approval of their line manager will be required.

For secondment projects, all secondees must comply with visa and immigration requirements. Please check with the MVLS HR team prior to applying.

Funding proposals must:

• describe the area of knowledge, including the underpinning research and the anticipated innovation to be developed;

• have a single, named PI who is responsible for the project, who must be a member of staff at the University of Glasgow;

• briefly outline the background research on which the proposed work is based on;

• describe the current stage of development and how it will be moved forward by the funding requested for the proposed IAA project;

• provide details on the existing needs for this work and the opportunities that will be addressed by this project. This can be backed up by evidence derived from the market, existing or identified stakeholders or any other impact drivers, where appropriate;

• outline the current barriers to impact;
• describe any competing technologies and the advantages of the proposed innovation;

• clearly present a budget breakdown per milestone, with timescales, including the value of contributions in-cash or in-kind from partners;
• describe the risks involved with each milestone and the mitigation plans in place to address these;

• provide details of anticipated project outcomes and impacts, including the way of achievement, anticipated timescales, and how the anticipated outcomes will be measured;

• demonstrate that all appropriate agreements and contracts are in place and an appropriate IP strategy is being considered or adopted (where applicable);
• state clear next steps, should the project be successful, along with potential benefits to the University of Glasgow;

• outline how responsible innovation, sustainability and Equality, Diversity and Inclusion (EDI) principals will be incorporated into your project.

IAA applications will be assessed by the TRI Management Review Panel and will consider the above criteria. Proposals that fail to address these criteria will be deemed ineligible for funding and may by rejected, or feedback given for resubmission. It is strongly encouraged that you discuss your proposal with the TRI management team before submitting your application.

Please see links to case studies of some of the previously funded MRC IAA projects, and a full list of funded projects below, listed by parent award round.

• Nebu~Flow: Next Generation of Nebulisers for Efficient Respiratory Drug Delivery
• VascuSens: Self-Reporting Vascular Graft Development
• Portage Glasgow Ltd: University of Glasgow Partners with Portage Pharmaceuticals
• Mitotargin: Developing novel diagnostics and therapeutics targeting the mitochondria
• Disruptyx Therapeutics: Developing the next-generation of precision peptide therapeutics against cancer